Savara Inc (NASDAQ:SVRA – Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,550,000 shares, an increase of 22.4% from the December 15th total of 2,900,000 shares. Based on an average daily volume of 730,400 shares, the short-interest ratio is presently 4.9 days. Currently, 5.2% of the company’s stock are short sold.
Insider Buying and Selling
In related news, CFO David L. Lowrance sold 10,000 shares of the company’s stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $4.71, for a total value of $47,100.00. Following the completion of the transaction, the chief financial officer now directly owns 342,355 shares of the company’s stock, valued at approximately $1,612,492.05. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, Director Nevan C. Elam sold 93,843 shares of the stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of $4.71, for a total transaction of $442,000.53. Following the completion of the transaction, the director now directly owns 22,500 shares in the company, valued at approximately $105,975. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO David L. Lowrance sold 10,000 shares of the stock in a transaction dated Thursday, December 28th. The stock was sold at an average price of $4.71, for a total transaction of $47,100.00. Following the transaction, the chief financial officer now owns 342,355 shares of the company’s stock, valued at $1,612,492.05. The disclosure for this sale can be found here. In the last ninety days, insiders sold 187,843 shares of company stock valued at $884,741. Company insiders own 4.58% of the company’s stock.
Institutional Trading of Savara
A number of hedge funds and other institutional investors have recently modified their holdings of SVRA. Royal Bank of Canada acquired a new position in shares of Savara during the second quarter worth $25,000. Jane Street Group LLC acquired a new position in shares of Savara during the third quarter worth $26,000. Squarepoint Ops LLC acquired a new position in shares of Savara during the first quarter worth $32,000. Citigroup Inc. acquired a new position in Savara in the fourth quarter valued at $33,000. Finally, Alliancebernstein L.P. acquired a new position in Savara in the second quarter valued at $38,000. Institutional investors own 97.28% of the company’s stock.
Savara Price Performance
NASDAQ:SVRA traded up $0.08 during mid-day trading on Friday, reaching $4.27. The stock had a trading volume of 513,349 shares, compared to its average volume of 873,922. The stock has a 50-day simple moving average of $4.12 and a two-hundred day simple moving average of $3.73. The stock has a market capitalization of $577.90 million, a PE ratio of -13.77 and a beta of 0.73. The company has a debt-to-equity ratio of 0.18, a current ratio of 18.98 and a quick ratio of 18.98. Savara has a 12 month low of $1.63 and a 12 month high of $4.97.
Savara (NASDAQ:SVRA – Get Free Report) last posted its earnings results on Thursday, November 9th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). On average, equities analysts anticipate that Savara will post -0.35 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on SVRA shares. Guggenheim started coverage on shares of Savara in a report on Tuesday, November 7th. They issued a “buy” rating and a $7.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Savara in a report on Monday, November 13th.
About Savara
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.